|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-7
|
|
pubmed:abstractText |
This open-label, prospective, multicenter single-arm phase II study combined bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma (GBM). The objectives were to determine the efficacy of this treatment combination and the associated toxicity.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating,
http://linkedlifedata.com/resource/pubmed/chemical/Dacarbazine,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab,
http://linkedlifedata.com/resource/pubmed/chemical/temozolomide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BlackKeithK,
pubmed-author:CloughesyTimothyT,
pubmed-author:ElashoffRobertR,
pubmed-author:FehrenbacherLouisL,
pubmed-author:FilkaEmeseE,
pubmed-author:GreenRichard MRM,
pubmed-author:KolevskaTatjanaT,
pubmed-author:LaiAlbertA,
pubmed-author:LiauLinda MLM,
pubmed-author:MischelPaul SPS,
pubmed-author:NghiemphuPhioanh LPL,
pubmed-author:PeakScottS,
pubmed-author:PhuphanichSurasakS,
pubmed-author:PolikoffJonathanJ,
pubmed-author:PopeWhitney BWB,
pubmed-author:SelchMichaelM,
pubmed-author:SolisOrestes EOE,
pubmed-author:SpierCynthia ECE,
pubmed-author:TranAnhA,
pubmed-author:YongWilliam HWH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
142-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21135282-Adult,
pubmed-meshheading:21135282-Aged,
pubmed-meshheading:21135282-Aged, 80 and over,
pubmed-meshheading:21135282-Angiogenesis Inhibitors,
pubmed-meshheading:21135282-Antibodies, Monoclonal,
pubmed-meshheading:21135282-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21135282-Antineoplastic Agents, Alkylating,
pubmed-meshheading:21135282-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21135282-Brain Neoplasms,
pubmed-meshheading:21135282-Combined Modality Therapy,
pubmed-meshheading:21135282-Dacarbazine,
pubmed-meshheading:21135282-Female,
pubmed-meshheading:21135282-Glioblastoma,
pubmed-meshheading:21135282-Humans,
pubmed-meshheading:21135282-Male,
pubmed-meshheading:21135282-Middle Aged,
pubmed-meshheading:21135282-Prospective Studies
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
|
|
pubmed:affiliation |
David Geffen School of Medicine at UCLA, Reed Neurological Research Center, Los Angeles, CA 90095, USA. albertlai@mednet.ucla.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
